17␤-Estradiol (E 2 ) rapidly (Ͻ20 min) attenuates the ability of -opioids to hyperpolarize guinea pig hypothalamic (␤-endorphin) neurons. In the current study, we used intracellular recordings from guinea pig hypothalamic slices to characterize the receptor and intracellular effector system mediating the rapid effects of E 2 . E 2 acted stereospecifically with physiologically relevant concentration dependence (EC 50 ϭ 8 nM) to cause a 4-fold reduction in the potency of a -opioid agonist to activate an inwardly rectifying K ϩ conductance. Using Schild analysis to estimate the affinity of the -opioid receptor for an antagonist (naloxone), we found that estrogen did not compete for the -opioid receptor or alter the affinity of the receptor. Both the nonsteroidal estrogen diethylstilbestrol and the "pure" antiestrogen ICI 164,384 blocked the actions of E 2 , the latter with a subnanomolar affinity. The protein synthesis inhibitor cycloheximide did not block the estrogenic uncoupling of the -opioid receptor from its K ϩ channel, implying a nongenomic mechanism of action by E 2 . The actions of E 2 were mimicked by the protein kinase A (PKA) activators forskolin and cAMP, Spisomer triethylammonium salt. Furthermore, the selective PKA antagonists cAMP, Rp-isomer triethylammonium salt and KT5720, which have different chemical structures and modes of action, both blocked the effects of E 2 . Thus, estrogen binds to a specific receptor that activates PKA to rapidly uncouple the -opioid receptor from its K ϩ channel. Because we have previously shown that ␥-aminobutyric acid B receptors are also uncoupled by estrogen, this mechanism of action has the potential to alter synaptic transmission via G protein-coupled receptors throughout the brain.
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Classically, the ER is thought to act by increasing transcription at estrogen-response elements (1) . However, it has become clear that ER actions are much more complex, involving multiple accessory proteins (2) and complex interactions with other intracellular systems (e.g., protein kinases) (3) . Furthermore, there is compelling evidence for the existence of nonclassic steroid receptors, some of which are in the plasma membrane (4 -7) . Finally, numerous rapid (Ͻ30 min), presumably nongenomic effects of E 2 are found in the brain and other tissues (8 -11) ; however, the pharmacology and cellular mechanisms of these effects are often poorly understood. Thus, despite the recent progress toward understanding the complexity of E 2 actions, it remains unclear how these diverse actions work together to regulate cellular physiology.
One well-characterized and vital action of E 2 is regulation of reproduction through negative feedback on the HPG axis. In vivo and in vitro studies in several species have shown that E 2 rapidly (Ͻ30 min) suppresses GnRH/luteinizing hormone release (12) (13) (14) . Although this estrogenic inhibition is thought to involve ␤-endorphin neurons that are presynaptic to GnRH cells (15) , the cellular mechanism by which ␤-endorphin neurons mediate the rapid regulation by estrogen of GnRH secretion remains unknown. However, ␤-endorphin preferentially binds to -opioid receptors (16) , and the vast majority (Ͼ90%) of hypothalamic neurons, including GnRH cells (17) , are hyperpolarized by -opioid activation of inwardly rectifying K ϩ currents (18) . Furthermore, a brief (20 min) exposure to E 2 rapidly reduces -opioid potency in ␤-endorphin but not GnRH neurons (17, 18) . The EC 50 value of the -opioid agonist DAMGO after the application of E 2 is nearly 4-fold greater than control values with no change in the efficacy. 17␣-Estradiol is a biologically inactive isomer of E 2 that is identical to the native steroid except for the configuration of a single hydrogen atom. The inability of this compound to mimic the effects of E 2 helped confirm the specificity of this response. Finally, we have also shown that the actions of E 2 occur at physiologically relevant concentrations.
In the current study, we characterized the receptor and intracellular effector system mediating the rapid attenuation by E 2 of -opioid response. Because PKA activation uncouples purified receptors from their G proteins (19) , we investigated the possibility that a protein kinase mediates the rapid actions of estrogen. We found that PKA stimulators mimicked the effects of E 2 and that two different PKA antagonists with different chemical structures and mechanisms of action blocked the effects of E 2 .
Materials and Methods
Animals. Female guinea pigs (Topeka; 350-600 g) that were born and raised in our colony were maintained on a 14-hr light/10-hr dark lighting schedule (lights on 6:30 a.m. to 8:30 p.m.) and were ovariectomized while under anesthesia with ketamine (33 mg/kg)/xylazine (6 mg/kg) 6-10 days before each experiment. Serum estrogen levels as determined by RIA (steroid RIA core, P30 HD18185) were Ͻ12 pg/ml (sensitivity of the RIA was 2.5 pg/ml) at the time of death. Each animal was decapitated between 9:00 and 10:00 a.m.; the brain was removed, the hypothalamus was dissected, and coronal slices of 450-m thickness were cut with a vibratome (18) . A single slice was submerged in an oxygenated (95% O 2 /5% CO 2 ), salt solution (aCSF) at 35 Ϯ 1°; the solution flowed through at a rate of 1.5 ml/min and contained 124 mM NaCl, 5 mM KCl, 1.25 mM NaH 2 PO 4 , 2 mM MgSO 4 , 2 mM CaCl 2 , 26 mM NaHCO 3 , 10 mM dextrose, and 10 mM HEPES.
Drugs. All drugs and chemicals were from Sigma Chemical (St. Louis, MO) unless otherwise specified. All drugs were dissolved in aCSF and then superfused over the slice. Drug changes were made using a manual three-way stopcock. Tetrodotoxin (1 M) was added to all drug solutions before application to ensure a postsynaptic effect. The -opioid responses were measured with the selective agonist DAMGO (20 nM-24 M; Peninsula Laboratories, Belmont, CA; Ref. 16 ) and antagonized with naloxone (20-320 nM; Ref. 16 ). E 2 , DES, and BSA-E 2 were from Steraloids (Wilton, NH), and ICI 164,384 [N-n-butyl-11-(3,17␤-dihydroxyestra-1,3,5(10)-trien-7␣-yl)-N-methylundecanamide] was the generous gift of Dr. Alan Wakeling (Zeneca Pharmaceuticals, Cheshire, UK). The E 2 had been recrystallized to ensure purity. E 2 , DES, and ICI 164,384 were stored at 4°i n a 1 mM 95% ethanol solution and dissolved in aCSF before application. We have shown previously that 17␣-estradiol in similar concentrations of ethanol did not alter -opioid responses (18) . Cycloheximide, forskolin, staurosporine, and KT5720 (Calbiochem, San Diego, CA) were dissolved in ethanol and then diluted in aCSF before application. Rp-cAMP and Sp-cAMP (Calbiochem) were dissolved in deionized H 2 O (10 mM) and then diluted in aCSF.
Electrophysiology. Intracellular recordings were made from arcuate neurons using techniques similar to those previously described (18) . Microelectrodes were made from borosilicate glass micropipettes (1-mm o.d.; Dagan, Minneapolis, MN) and were filled with a 3% biocytin solution in 1.75 M KCl and 0.025 M Tris, pH 7.4; resistances varied from 100 to 250 M⍀. Intracellular potentials were amplified, and current was passed through the electrode using an Axoclamp 2A (Axon Instruments, Burlingame, CA). Current and voltage traces were recorded on a chart recorder (model 2200; Gould, Cleveland, OH), digitized at 83 Hz, and stored on an IBM PC clone with Axotape software (Axon Instruments). Voltage-current relationships were obtained by applying a series of depolarizing and hyperpolarizing current pulses (1-sec) and measuring the voltage at the end of each step. Voltage-matched voltage-current plots were also done during the drug-induced hyperpolarization to determine the reversal potential of the conductance. Similarly, voltage-current plots were generated before and during the application of all steroids and kinase analogs to ensure that there were no direct effects on membrane conductances.
Pharmacology. Cumulative concentration-response curves were generated by applying increasing concentrations of DAMGO until the drug-induced hyperpolarization reached a new steady level, usually after 6-7 min (e.g., Fig. 1A ). The EC 50 value was calculated using SigmaPlot (Jandel Scientific, Costa Madre, CA) software to determine the best fit to the logistic equation. The K e value for naloxone was estimated by Schild analysis (20) , and the values for control cells and E 2 -sensitive cells were compared after the application of 100 nM E 2 .
The concentration dependence of estrogen action was assessed by performing DAMGO concentration-response curves after the application of varying concentrations of E 2 (1 nM to 1 M). Many cells were tested with multiple E 2 concentrations. In another series of experiments, slices were superfused with 1 or 2 nM ICI 164,384 for 15 min before E 2 . The response to E 2 was calculated using the following relation: (DAMGO EC 50 after E 2 )/(DAMGO EC 50 before E 2 ) ϫ 100%. The data were computer fitted to the logistic equation to generate an E 2 concentration-response curve.
Immunocytochemistry. Hypothalamic slices that had been incubated with aCSF (time in aCSF, 3-6 hr), estrogen (time after E 2 , 2-6 hr), or cycloheximide followed by estrogen (time after E 2 , 2-6 hr) were prepared for immunocytochemistry as previously described in detail (21) . Briefly, after fixation and cryostat sectioning, the sections mounted on slides were incubated with rat ER antibody (H222; a gift from Dr. Geoffrey Greene, University of Chicago School of Medicine) at 1.0 g/ml for 40 hr at 4°. Next, the slides were washed for 30 min in phosphate buffer, pH 7.4. Then, the sections were incubated with donkey anti-rat IgG conjugated to Cy3 at 1:100 dilution (Jackson ImmunoResearch, West Grove, PA) for 2 hr at room temperature. Finally, the slides were washed in phosphate buffer for a minimum of 2 hr, and the sections were coverslipped with glycine-buffered glycerol, pH 7.4. The ER staining was photographed with Tri-X-Pan film (ASA 400; Eastman Kodak, Rochester, NY) on a Zeiss Axiophot microscope. To determine the number of cells con- Upper dashed line, predrug membrane potential (Ϫ51 mV). Lower dashed line, maximal DAMGO-induced hyperpolarization (Ϫ62 mV). Transient downward deflections represent the response to current pulses (100 msec, 50 pA) used to monitor input resistance. Arrow, membrane potential was current-clamped to the predrug resting potentials to verify that DAMGO caused a decreased input resistance. B, After washout of the drugs, a cumulative concentration-response curve was performed (F) and compared with pre-E 2 control responses to DAMGO (E). Line through data, computer-generated fit to the logistic equation. C, Current-voltage plot performed by applying current steps (1 sec, 0.2 Hz) before (E) and during (F) E 2 showed that this steroid did not alter resting conductances. taining immunoreactive ERs, the cells within 250 m 2 on each section were counted under fluorescent illumination using an eyepiece square grid reticle on a Leitz Laborlux microscope. Two or three sections from the arcuate area of each slice were counted without knowledge of the treatment groups. The total number of cells that were counted from the different sections were averaged, and the mean number of cells was used for further analysis.
Statistical analysis. Numerical data are expressed as mean Ϯ standard error. Electrophysiological data were compared using an unpaired two-tailed Welch t test, except as noted. A value of p Ͻ 0.05 was considered significant. The mean DAMGO EC 50 value (114 Ϯ 9 nM, 65 cells) after E 2 (including both E 2 -sensitive and -insensitive cells) was significantly different from controls ( p Ͻ 0.0001) and was compared with the DAMGO EC 50 values after E 2 plus kinase/estrogen antagonists with the use of a Mann-Whitney test to evaluate those agents. In the immunocytochemical studies, statistical differences among these groups were determined using an analysis of variance with a Tukey-Kramer post hoc test.
Results
Estrogen rapidly attenuates the -opioid response in hypothalamic neurons. E 2 rapidly (20 min) reduces the potency of the -opioid agonist DAMGO, causing a nearly 4-fold, parallel shift in the DAMGO dose-response curve in approximately one third of hypothalamic cells (53 cells) (18) . To further characterize this time course, we applied submaximal concentrations of DAMGO and E 2 simultaneously (Fig.  1A) . Although E 2 does not reduce the maximal response to DAMGO (18) , it reduced the response to a submaximal -opioid concentration as the cell re-equilibrated to the lower potency state. The response to 100 nM DAMGO before E 2 was Ϫ9 mV hyperpolarization (82% maximum). However, when 20 nM E 2 was added, the DAMGO response was diminished within 7 min, and after ϳ12 min, the DAMGO response equilibrated to Ϫ4 mV (36% maximum response) below the resting membrane potential. There was no desensitization when this same cell was subsequently tested with higher concentrations of DAMGO (up to 300 nM for 18 min). 1 In our preparation, the response to even higher DAMGO concentrations (1 M) caused no obvious desensitization in hypothalamic cells (mean change ϭ 0.12 Ϯ 0.08 mV; 13 cells), and E 2 did not increase the desensitization to 1 M DAMGO in E 2 -sensitive cells (mean change ϭ 0.15 Ϯ 0.04 mV; 17 cells). Furthermore, we have shown previously that E 2 alters DAMGO potency without prior exposure to -opioids (18) . Thus, the attenuated DAMGO response after E 2 does not appear to be due to homologous desensitization of the -opioid receptor.
After the washout of DAMGO and E 2 , a complete DAMGO concentration-response curve showed that the DAMGO EC 50 value (177 nM) was shifted from pre-estrogen controls (EC 50 ϭ 59 Ϯ 3 nM; 43 cells) (Fig. 1B) . Furthermore, current/voltage relationships generated before and during the application of 20 nM E 2 alone showed that this steroid did not directly alter ion channels (Fig. 1C) . Therefore, estrogen rapidly attenuates the DAMGO response by altering the potency at the -opioid receptor.
Estrogen acts via a specific receptor. The parallel, rightward shift in the DAMGO concentration-response curve induced by E 2 is consistent with a competitive block of the -opioid receptor, similar to what has been seen with pharmacological concentrations of E 2 (Ϸ200 M; Ref. 22 ). This possibility was investigated using Schild analysis (20) to determine the affinity of the receptor for the opioid antagonist naloxone (16) before and after estrogen. As seen in Fig.  2 , the K e value for naloxone in cells treated with 100 nM E 2 was not different from that of control cells. Furthermore, both Schild plots have a slope of Ϫ1.0, which is consistent with competitive blockade of the -opioid receptor with naloxone. This would not be true if E 2 were competing with both naloxone and DAMGO for the -opioid binding site (23) . Thus, E 2 neither alters the affinity of the -opioid receptor for antagonist nor competitively blocks it.
The receptor mediating the rapid effects of E 2 was further characterized using the antiestrogen ICI 164,384 and the nonsteroidal estrogen DES. Although DES binds to the classical ER and is an agonist for the genomic effects of E 2 , this compound did not alter the response to -opioids (100 nM DES, DAMGO EC 50 ϭ 69 Ϯ 5 nM; seven cells). However, DES (100 nM) blocked the actions of 20 nM E 2 when these two compounds were superfused together (DAMGO EC 50 ϭ 53 Ϯ 4 nM; nine cells; p Ͻ 0.0001) (Fig. 3) . Thus, DES acts as an estrogenic agent, although it is an antagonist rather than an agonist in this system. To our knowledge, this is the first described system in which DES is an estrogen antagonist. However, a similar mixed agonist/antagonist action at classic ERs has been described for other nonsteroidal estrogens, such as tamoxifen (24) . ICI 164,384 is a well-characterized, competitive estrogen antagonist (25) . As seen in Fig. 4A , ICI 164,384 (100 nM) blocks E 2 (20 nM) action (DAMGO EC 50 ϭ 61 Ϯ 4 nM; seven cells; p Ͻ 0.0001). Further studies generated E 2 concentration-response curves by superfusing E 2 (1 nM to 1 M; 53 cells) followed by a complete concentrationresponse profile to DAMGO. In several cases, multiple con- Fig. 2 . Estrogen does not compete for the -opioid receptor. A representative response in a cell before E 2 (E) in which the DAMGO EC 50 was shifted from 56 nM to 275, 1047, and 9126 nM by (Ç) 20, (ϫ) 80, and (Ⅺ) 320 nM naloxone, respectively. Inset, Schild analysis was used to estimate the K e value for naloxone. Lines, linear regression fit of the data. The slopes of both lines are Ϫ1.0, which satisfies the criterion for Schild analysis with a single competitive antagonist (20) . The K e value for naloxone before E 2 (E, 4.0 nM; four cells) was not different from that for E 2 -sensitive cells after E 2 (F, 3.2 nM; six cells) despite a 3-fold shift of the DAMGO EC 50 value (from 57 Ϯ 2 to 171 Ϯ 12 nM, respectively). centrations of E 2 were applied to the same cell, each followed by a DAMGO concentration-response curve. As seen in Fig.  4B , E 2 had a maximal effect of increasing the DAMGO EC 50 value (V max ) by 376%. The EC 50 value for the actions of estrogen was 7.5 nM, and the Hill slope was 0.7. A second estrogen concentration-response curve was then generated in which 1 nM ICI 164,384 was superfused before and during E 2 (six cells). The resulting concentration-response curve had an EC 50 value of 23 nM, a Hill slope of 0.6, and a V max of 372%. A third E 2 concentration-response curve was generated in the presence of 2 nM ICI 164,384, resulting in an EC 50 value of 81 nM, a Hill slope of 1.1, and a V max of 375%. A modified, single-point Schild analysis (23) estimated the K e value of ICI 164,384 to be 0.48 and 0.20 nM after treatment with 1 and 2 nM ICI 164,384, respectively. This is very similar to what has been reported for the classic ER (K d ϭ 0.7 nM; Ref. 25) .
Inhibition of protein synthesis does not block the effects of E 2. The question arises of what is the biochemical mechanism of the rapid effects of E 2 . A genomic mechanism seems unlikely because E 2 requires Ն30-60 min to alter protein synthesis (26) and probably a longer time to affect cellular physiology. Moreover, cycloheximide did not block the rapid effects of E 2 . Slices were superfused with 200 M cycloheximide for 30 min before, during, and 30 min after E 2 (100 nM, 20 min). This treatment has been shown to block Ͼ90% of protein synthesis in brain slices (27) but was unable to block the effects of E 2 (DAMGO EC 50 ϭ 115 Ϯ 28 nM; eight cells with three cells having a DAMGO EC 50 value of Ͼ160 nM) (Fig. 5) . To help confirm that this cycloheximide treatment did indeed block protein synthesis, we made use of the fact that E 2 causes a protein synthesis-dependent downregulation of the ER (28) . Consistent with these previous findings, we found that E 2 caused a robust decrease in the number of cells stained with an anti-ER antibody (77 Ϯ 3 cells/250-m 2 field in control slices versus 12 Ϯ 4 cells in E 2 -treated slices; p Ͻ 0.001) and that this effect was blocked with prior cycloheximide treatment (78 Ϯ 7 cells; p Ͻ 0.001 versus controls; Fig. 6 ). PKA stimulators mimic the effects of E 2. Research in other systems has shown that protein kinases can uncouple opioid receptors from their effector systems (19) , and the rapid effects of E 2 have been shown to be mediated by increases in intracellular cAMP levels in neural (29) and nonneural (9) tissues. We tested the hypothesis that the rapid effects of estrogen are mediated by nongenomic stimulation of PKA. Stimulation of AC with forskolin (1-25 M) decreased DAMGO potency (DAMGO EC 50 ϭ 105-221 nM; six cells). Furthermore, direct PKA activation by superfusion of the nonhydrolyzable cAMP analog Sp-cAMP (Fig. 7A ) mimicked E 2 action in a concentration-dependent manner. A concentration-response curve for Sp-cAMP (similar to the E 2 concentration-response curve shown in Fig. 4B ) estimated the EC 50 value for Sp-cAMP to be 84 M, with a maximal When DES (100 nM; nine cells) was superfused for 10 min before and during E 2 (20 nM, 20 min), the effects of E 2 were blocked. The DAMGO EC 50 value in this representative cell was 46 nM after the application of DES plus E 2 (Ç). However, when E 2 alone was applied to the same cell, the DAMGO EC 50 value was increased to 194 nM (F). Dashed line, summary of pre-E 2 DAMGO concentration-response curves (EC 50 ϭ 59 Ϯ 3 nM). Inset, Molecular structure of DES. PKA inhibitors block the effects of E 2 . To further assess the involvement of protein kinases in modulating -opioid responses, the nonselective protein kinase inhibitor staurosporine (100 nM) was superfused before (10 min) and during (20 min) E 2 (100 nM) (Fig. 7B) . Staurosporine blocked the effects of E 2 , with a mean DAMGO EC 50 value of 45 Ϯ 6 nM (11 cells) that was significantly lower than in cells treated with E 2 alone ( p Ͻ 0.0001). Similarly, in an E 2 -sensitive cell (post-E 2 DAMGO EC 50 ϭ 143 nM), application of staurosporine (10 nM) after E 2 reduced the DAMGO potency (DAMGO EC 50 ϭ 46 nM). Thus, staurosporine both blocked the induction and reversed a previously established estrogenic modulation of -opioid potency. To confirm that PKA is the protein kinase mediating E 2 action, we used chemically dissimilar compounds that selectively inhibit PKA through different mechanisms. Rp-cAMP is a nonhydrolyzable cAMP analog that blocks PKA activation by binding the regulatory subunit (30) . In contrast, KT5720 is an analog of staurosporine that selectively inhibits PKA at its catalytic site (31) . Prior application of either agent blocked E 2 action. The DAMGO EC 50 value (47 Ϯ 7 nM; seven cells) in cells treated with KT5720 (60 nM) plus E 2 (100 nM) was not different from that of controls but was significantly less than that of E 2 -treated cells ( p Ͻ 0.0005). Similar effects were seen when Rp-cAMP (100 M) was used instead of KT5720 (DAMGO EC 50 ϭ 57 Ϯ 7 nM; eight cells; p Ͻ 0.0001). After these experiments, the same cells were superfused with E 2 alone, which reduced the DAMGO potency, confirming the E 2 sensitivity of these cells. Finally, the actions of E 2 were reversed by Rp-cAMP and mimicked by Sp-cAMP in the same cell (Fig. 8) . In a different cell, KT5720 also reversed the actions of E 2 . Thus, PKA inhibitors block the induction of the rapid actions of estrogen and reverse a previously established effect.
Discussion
The current results describe the receptor and intracellular effector system that mediates a novel action of E 2 to rapidly alter synaptic transmission. E 2 seems to act via a specific receptor because the actions of E 2 are saturable, with a physiologically relevant concentration dependence and are not mimicked by the biologically inactive isomer 17␣-estra- Estrogen Modulates -Opioid Receptors via PKA diol (18) . This steroid did not compete for -opioid receptors. Furthermore, the lipophilic estradiol diffuses freely across cell membranes, but by covalently linking E 2 at its C6 position to BSA-E 2 , the steroid is rendered cell-impermeant. Although this conjugate binds to extracellular E 2 receptors and is biologically active in other cell types (7), BSA-E 2 did not alter the response of hypothalamic neurons (eight cells) to -opioids. 2 In addition, pharmacological characterization revealed that the antiestrogen ICI 164,384 blocked the effects of E 2 with a subnanomolar affinity (25) . Furthermore, although the molecular structures of E 2 and DES are quite different, DES serves as an estrogenic agent at both the classic ER and the currently described ER. However, DES mimics the genomic effects of E 2 , but this compound was an antagonist in our system. Although the currently described receptor is similar to the classic receptor, the pharmacodynamics of E 2 and the antagonism by DES imply that a different ER is mediating this effect. Perhaps these E 2 effects are mediated by one of the isoforms of the classic ER that have been found in the brain (4) . Therefore, the currently described phenomenon may be mediated by a novel ER or a novel action of the classic ER.
PKA mediates the rapid modulation by estrogen of -opioid potency. PKA did not play a simply permissive role in E 2 action because PKA activators altered -opioid response in the absence of added steroid. Conversely, inhibition of PKA by two chemically and mechanistically different compounds confirmed that PKA is mediating (rather than merely mimicking) E 2 action. Finally, preliminary data indicate that treatment of hypothalamic slices with E 2 , but not with 17␣-estradiol, for 10 min stimulates 32 P-incorporation into a PKA substrate peptide. 3 Although the estrogenic activation of PKA is clear, the mechanism of this stimulation remains to The rapid attenuation by estrogen of DAMGO potency is blocked by PKA inhibitors. When E 2 -sensitive and -insensitive cells were combined, the DAMGO EC 50 value (114 Ϯ 9 nM; 65 cells) was significantly higher than that of controls. Staurosporine (100 nM) and the more selective PKA inhibitors KT5720 (60 nM; seven cells) and RpcAMP (100 M; eight cells) blocked the effects of E 2 (100 nM, 20 min) when these agents were superfused for 10 min before and during E 2 . After the generation of these DAMGO concentration-response curves, E 2 was subsequently applied alone and shown to reduce DAMGO potency (data not shown), thus confirming that each of these kinase inhibitors blocked the actions of estrogen in E 2 -sensitive neurons. Staurosporine caused a small but significant reduction in the DAMGO EC 50 value compared with that for controls. However, none of these agents had any other effect on either the passive or DAMGO-induced properties of these cells. ‫,ءء‬ p Ͻ 0.0001; ‫,ء‬ p Ͻ 0.01 compared with controls. be determined. However, the ability of Rp-cAMP to reverse E 2 action suggests that estrogenic activation of PKA involves increases in cAMP levels rather than direct stimulation of the kinase (10) . Perhaps E 2 stimulates the activity of AC or inhibits a phosphodiesterase. Finally, it remains to be determined whether other intracellular effectors (e.g., protein kinase C) are also involved in transducing the rapid effects of estrogen. Nevertheless, along with the well-described genomic and plasma membrane-delimited actions of E 2 , the present intracellular messenger broadens our understanding of how E 2 regulates cellular physiology.
In addition to heterologous control by E 2 , PKA may be involved in homologous regulation of -opioid receptors. Chronic exposure to morphine causes a similar uncoupling of -opioid receptors from their potassium channels (32) . Furthermore, -opioids inhibit AC, and chronic inhibition by morphine results in a compensatory up-regulation of AC and PKA (33) . Changes in PKA have been correlated with the development of morphine tolerance and dependence (33) . However, previous studies have been unable to show a PKAinduced reduction in the maximal -opioid response (34, 35) . To our knowledge, the current study is the first report that PKA decreases -opioid potency in neurons. Perhaps the up-regulation of PKA seen with chronic morphine causes an uncoupling of receptors from their effector systems, similar to what has been shown for ␤-adrenergic receptors (36) . Because ␤-endorphin neurons develop tolerance to chronic morphine (37) and are sensitive to rapid E 2 effects (18), it may be that acute E 2 and chronic morphine share some of the same mechanisms (i.e., increased PKA activity). Studies are under way to examine the effects of PKA modulators in morphinetolerant animals.
In addition, the currently described phenomenon provides a cellular substrate for the rapid inhibition by estrogen of the HPG axis. We have found that both ␤-endorphin and GnRH neurons are hyperpolarized by -opioids (17, 18) and have proposed a model for negative feedback of estrogen on GnRH release. Because the receptor is an autoreceptor on ␤-endorphin neurons, a given ␤-endorphin cell would be hyperpolarized by its own neurotransmitter. Therefore, the rapid attenuation by E 2 of -opioid potency in ␤-endorphin neurons (18) would uncouple ␤-endorphin autoinhibition. This would cause increased opioid peptide release with subsequent inhibition of GnRH neuronal activity (17) . Furthermore, modulation of -opioid potency occurs within a few minutes and requires nanomolar E 2 concentrations, whereas genomic actions of E 2 require hours to days to alter cellular physiology and act with subnanomolar potency (26, 38) . Thus, E 2 may have different actions depending on the time and concentration of E 2 , as has been predicted by research in animal models (39) . Finally, because we have recently shown that E 2 can rapidly alter the potency at the ␥-aminobutyric acid B receptor (40) , estrogen may modulate a variety of G proteincoupled receptors that participate in regulation of the HPG axis.
The genomic effects of E 2 have often been assumed to be the sole pathway for steroid actions. The recent discovery of membrane-delimited estrogen actions has added to the complexity of E 2 physiology, resulting in a dichotomy between extremely rapid membrane effects and slow nuclear actions. Estrogenic activation of PKA is a mechanism for rapid alteration of synaptic transmission that may both complement and complete the other modes of E 2 action. These findings extend the range of E 2 actions from months to minutes and from the nucleus to the extracellular membrane. Although we must further characterize the pharmacology and physiology of these various actions and the interactions among them, we are beginning to develop a more comprehensive picture of how E 2 actually works.
